TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28355979
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy care
Study: 28355979
Drug: SBST administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBST administered at different time points
Study: 24434827
Drug: Daily feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily feedback messages (DFB group; n = 70)
Study: 22509750
Drug: 0.5% MF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% MF gel
Study: 22509750
Drug: 1% MF
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1% MF gel
Study: 22509750
Drug: 1.5% MF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% MF gel
Study: 21365405
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program (quarterly follow-up by a hospital pharmacist for 9 months)
Study: 21365405
Drug: No pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmaceutical care (control group)
Study: 14576536
Drug: 0.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg/kg succinylcholine (saline control)
Study: 14576536
Drug: 0.24 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 mg/kg succinylcholine
Study: 3937549
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg, oral, twice daily)
Study: 27887597
Drug: Ability Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ability Program (tablet-delivered cognitive activities 5 days/week, physical activities 7 days/week)
Study: 27887597
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) (paper and pencil cognitive activities 5 days/week, clinician's prescribed physical exercise daily)
Study: 9388311
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (dextran, nicotinic acid, aspirin, dipyridamole, radix salviae miltiorrhizae composita)
Study: 27077879
Drug: 25 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL/day of PC-enriched OO containing 500 mg PC/kg (FVOO)
Study: 27077879
Drug: 25 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL/day of OO containing 80 mg PC/kg (VOO)
Study: 27077879
Drug: 25 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL/day of OO containing a mixture of 500 mg PC/kg from OO and thyme (FVOOT)
Study: 22422361
Drug: Dolutegravir 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 250 mg suspension
Study: 22422361
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg tablet
Study: 21252455
Drug: Short-course acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-course acyclovir therapy (800 mg five times a day for four days)
Study: 9307221
Drug: poly(L-lactide) osteosynthesis
Normalized name: L-(-)-lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly(L-lactide) osteosynthesis plug
Study: 8354200
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins A and E (5000 IU + 100 IU)
Study: 8354200
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of beta-carotene
Study: 2872913
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant groups (Groups B and C)
Study: 30789384
Drug: Mannitol 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.7 g/kg
Study: 30789384
Drug: Mannitol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 1.0 g/kg
Study: 30789384
Drug: Mannitol 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 1.4 g/kg
Study: 20026804
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m²/d
Study: 16001233
Drug: Tesaglitazar 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 1.0 mg/day
Study: 12556267
Drug: 2-implant overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-implant overdenture
Study: 10657821
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated influenza vaccine
Study: 1500660
Drug: Other antacids
Normalized name: ANTACIDS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antacids (magnesium hydroxide and aluminum hydroxide)
Study: 25765698
Drug: Clinic plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic plus community support (screening for serum cryptococcal antigen, antifungal therapy for positive cases, weekly home visits for 4 weeks)
Study: 23340440
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) gel, 0.5mL injection
Study: 19386741
Drug: Oligofructose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose supplementation (21 g/d)
Study: 18596121
Drug: multitarget therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: multitarget therapy (mycophenolate mofetil, tacrolimus, and steroids)
Study: 18596121
Drug: intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous cyclophosphamide (IVCY)
Study: 1951163
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate (FOC) supplemented with 15 mg alpha-tocopherol/d for 10 weeks
Study: 1951163
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate (FOC) plus an additional 200 mg alpha-tocopherol/d for 8 weeks (FOC+E)
Study: 7033573
Drug: Allopurinol during
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol during chemotherapy
Study: 7033573
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no allopurinol) during chemotherapy
Study: 26186592
Drug: Rikkunshito 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito 5.0 g/day
Study: 26186592
Drug: Rikkunshito 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito 2.5 g/day
Study: 27105601
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg)
Study: 27105601
Drug: Chlordiazepoxide (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (75 mg)
Study: 19001508
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg per day
Study: 15917194
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g intravenous infusion for 45 min)
Study: 8942013
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium, vitamin D3, and ascorbic acid supplementation
Study: 1705725
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation (Group I); 1.8 to 2.3 Gy once a day, total dose 30 to 40 Gy, average treatment duration 20 days
Study: 1705725
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation (Group II); 1.8 to 2 Gy two times a day, total dose 25 to 35 Gy, average treatment duration 10 days
Study: 30267478
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg i.v., maximum 8 mg)
Study: 30267478
Drug: Label dosing
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Label dosing of Diazepam
Study: 23221187
Drug: 10% povidone
Normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% povidone iodine aqueous solution (PI)
Study: 16638499
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg/day for 4 weeks)
Study: 10949538
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) melatonin, average final dose 5.7 mg (2-12 mg)
Study: 2864857
Drug: Nifedipine monotherapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine monotherapy (10 mg three times daily)
Study: 2864857
Drug: Metoprolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol monotherapy (100 mg twice daily)
Study: 2864857
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (100 mg metoprolol twice daily plus 10 mg nifedipine three times daily)
Study: 29373333
Drug: Ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine + Sufentanil (2 mg/ml ropivacaine and 0.25 μg/ml sufentanil)
Study: 29373333
Drug: Ropivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine alone (2 mg/ml ropivacaine)
Study: 20809058
Drug: Control rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control rTMS (sham treatment)
Study: 12663288
Drug: Fortified beverage
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified beverage with 10 micronutrients at physiologic doses
Study: 8650875
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of normal saline (15 mL/kg)
Study: 8650875
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg; maximum, 40 mg)
Study: 1632390
Drug: IS-5-MN (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IS-5-MN (20 mg) at 8 a.m.
Study: 1632390
Drug: IS-5-MN (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IS-5-MN (20 mg) at 2 p.m.
Study: 4056843
Drug: Recombinant DNA-derived
Normalized name: somatropin (recombinant DNA origin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a low dose of 2 X 10(6) U/m2 intramuscularly daily
Study: 4056843
Drug: Recombinant DNA-derived
Normalized name: somatropin (recombinant DNA origin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose of 20 X 10(6) U/m2 intramuscularly daily
Study: 4056843
Drug: Recombinant DNA-derived
Normalized name: somatropin (recombinant DNA origin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose (20 X 10(6) U/m2)
Study: 28795387
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/day orally) plus Fuzheng Kang'ai Formula (250 mL, twice per day, orally)
Study: 20123223
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (turning by nursing staff)
Study: 16361173
Drug: Penehyclidine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine hydrochloride (PH) 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Study: 16361173
Drug: Atropine 0.02
Normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Study: 12143227
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg terlipressin i.v. every 4 hours for 2 days (group I)
Study: 12143227
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg terlipressin i.v. every 4 hours for 5 days (group II)
Study: 9491067
Drug: White dawn
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 250 lux)
Study: 9491067
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 2 lux)
Study: 9491067
Drug: White dawn
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White dawn treatment
Study: 7923305
Drug: Standard nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nicardipine tablets
Study: 3044874
Drug: Dipyrone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (500 mg)
Study: 11811084
Drug: Standard eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard eradication treatment (lansaprasol 30 mg bid, clarithromycin 500 mg bid, amoxicillin 1 g bid for 14 days)
Study: 11811084
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 1000 mg/day plus standard treatment
Study: 11811084
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 1000 mg/day for 14 days
Study: 11811084
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen plus beta carotene (BC) 120 mg/day
Study: 11811084
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (BC) 120 mg/day for 14 days
Study: 30589387
Drug: 4-week rehabilitation
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week rehabilitation program consisting of ankle stretching and strengthening, balance training, and joint mobilizations, with daily home ankle-strengthening and stretching exercises.
Study: 29708388
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment plus exercise intervention (ST + EX)
Study: 29708388
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment plus wellness education (ST + CTRL)
Study: 17389305
Drug: LY451395 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY451395 0.2 mg BID for 28 days and 1.0 mg BID thereafter (n = 90)
Study: 14693973
Drug: Traditional primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional primary care treatment (Control)
Study: 12154416
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (n = 188)
Study: 8206467
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (70% ethanolic vehicle)
Study: 129853
Drug: Spectinomycin hydrochloride
Normalized name: Spectinomycin Hydrochloride
DrugBank: Spectinomycin (DB00919)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spectinomycin hydrochloride (2.0 g)
Study: 31676651
Drug: Full HPSF
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full HPSF (daily healthy lunch and structured physical activity sessions)
Study: 28448266
Drug: Transdermal Continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Continuous Oxygen Therapy (TCOT)
Study: 28448266
Drug: Moist Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist Wound Therapy (MWT) with sham device (control)
Study: 16863564
Drug: Bifidobacterium infantis
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium infantis 35624 at a dose of 1 x 10(8) cfu/mL
Study: 16863564
Drug: Bifidobacterium infantis
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium infantis 35624 at a dose of 1 x 10(6) cfu/mL
Study: 16863564
Drug: Bifidobacterium infantis
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium infantis 35624 at a dose of 1 x 10(10) cfu/mL
Study: 3015019
Drug: Daily acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily acyclovir treatment (200 mg t.i.d.)
Study: 3015019
Drug: Weekend acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekend acyclovir treatment (400 mg t.i.d. on Saturday and Sunday)
Study: 30286746
Drug: Managing multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Managing multiple medications
Study: 16190390
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy and UTI after hemorrhage (Group II)
Study: 16190390
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy (Group I)
Study: 12204667
Drug: Continue tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue tamoxifen treatment
Study: 12204667
Drug: Stop tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop tamoxifen treatment
Study: 10527998
Drug: HGF concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF concentrations in SGA group (16.9 ± 6.6 ng/ml)
Study: 10527998
Drug: HGF concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF concentrations in AGA group (16.7 ± 9.0 ng/ml)
Study: 10527998
Drug: HGF concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF concentrations in LGA group (20.2 ± 14.8 ng/ml)
Study: 7424807
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (45 g protein)
Study: 7424807
Drug: Sulfur amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfur amino acid supplement (15 g protein plus sulfur amino acids)
Study: 7424807
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (15 g protein)
Study: 31274775
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 µg/kg/min)
Study: 31274775
Drug: Milrinone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (0.4 µg/kg/min)
Study: 28898204
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (BPS) plus Aspirin (40 μg, tid and 100 mg, qd)
Study: 26135078
Drug: Internet usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet usage (not specified if treatment or control).
Study: 17902062
Drug: Potassium-magnesium-aspartate solution
Normalized name: potassium magnesium aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-magnesium-aspartate solution (Inzolen)
Study: 7950508
Drug: Hydrocortisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (30 mg/day)
Study: 7950508
Drug: Prednisone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (7.5 mg/day)
Study: 3604885
Drug: Sotalol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (160 to 800 mg/day, median 323 mg, mean 386 mg)
Study: 236804
Drug: Metiamide 1
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metiamide 1 g daily by mouth
Study: 21272413
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate supplementation (15 mg/d)
Study: 21272413
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate supplementation (30 mg/d)
Study: 11384788
Drug: Incentives to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentives to improve follow-up for tuberculosis therapy after release from jail
Study: 11384788
Drug: Outreach efforts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outreach efforts in shelters and drug/alcohol programs
Study: 9400508
Drug: Doxorubicin-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-based adjuvant chemotherapy
Study: 8121914
Drug: 32P with
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32P with low-dose hydroxy-urea (500 mg/day) maintenance therapy
Study: 8121914
Drug: 32P without
Normalized name: Sodium phosphate (32P)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32P without hydroxy-urea maintenance therapy
Study: 3303287
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg three times daily for 2 weeks
Study: 3303287
Drug: Nicardipine 20-40
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20-40 mg three times daily during an open study in 30 patients
Study: 30489620
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with remifentanil hydrochloride and propofol
Study: 21593649
Drug: Orafti Synergy1
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orafti Synergy1 (50 oligofructose:50 FOS) 0.4 g/dL
Study: 21593649
Drug: Orafti Synergy1
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orafti Synergy1 (50 oligofructose:50 FOS) 0.8 g/dL
Study: 21593649
Drug: GOS:FOS (90:10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS:FOS (90:10) 0.8 g/dL
Study: 12551829
Drug: Nadroparin (2,850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (2,850 IU subcutaneously daily for 90 days)
Study: 12551829
Drug: Warfarin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (1 mg orally daily for 90 days)
Study: 6638906
Drug: Metronidazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1000 mg vaginally preoperatively and 500 mg intravenously during surgery)
Study: 22431675
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) (various doses)
Study: 18240113
Drug: Schema-focused Emotive
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-focused Emotive Behavioural Therapy (SET)
Study: 9456256
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim (1 microg/kg daily, adjusted up to 10 microg/kg daily)